Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 5/20 | 0.57 |
| ▸ | ELOC | Q15369 | 3/20 | 0.55 |
| ▸ | ELOB | Q15370 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15126261 | 0.97 | VHL (0.59) | VHLELOCELOBMEN1KMT2A | |
| SCHEMBL21696687 | 0.97 | VHL (0.59) | VHLELOCELOBMEN1KMT2A | |
| SCHEMBL21697218 | 0.92 | VHL (0.56) | VHLELOCELOBPOLBF2 | |
| SCHEMBL16277209 | 0.91 | VHL (0.57) | VHLELOCELOBF2CYP3A4 | |
| SCHEMBL21696667 | 0.90 | PKM (0.58) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL21696541 | 0.89 | VHL (0.57) | VHLELOCELOBF2CYP3A4 | |
| SCHEMBL21696612 | 0.88 | VHL (0.51) | VHLELOCELOBMEN1KMT2A | |
| SCHEMBL21696751 | 0.88 | VHL (0.58) | VHLELOCELOBMEN1KMT2A | |
| SCHEMBL21697385 | 0.88 | VHL (0.53) | VHLELOCELOBF2CYP3A4 | |
| SCHEMBL21696951 | 0.88 | ALDH1A1 (0.56) | VHLELOCELOBCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | VHL 1/4885ELOC 190/4885ELOB 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.